Thimerosal Preservative

Thimerosal is a mercury-based preservative that has been used for decades in the United States in multi-dose vials (vials containing more than one dose) of some vaccines to prevent the growth of ger...

Kadcyla (ado-trastuzumab emtansine)

Kadcyla™ (ado-trastuzumab emtansine or T-DM1) for the treatment of people with HER2-positive metastatic breast cancer (mBC) who have received prior treatment with Herceptin® (trastuzumab)...

Prostate Cancer

Prostate cancer is the most common cancer in men in the UK; affecting 250,000 men. Risk factors for prostate cancer include age (average age at diagnosis is 70), a family history and a Caribbean or...

Anthrax Vaccines and Therapeutics

Anthrax is a zoonotic disease caused by the spore-forming bacterium Bacillus anthracis. The disease most commonly occurs in mammals (e.g., cattle, sheep, goats, camels, antelope. Anthrax occurs in hu...

Glybera

uniQure has developed Glybera as a therapy for patients with the genetic disorder lipoprotein lipase deficiency. LPLD is an orphan disease for which no treatment exists today. The disease is caused...

Protalex reports Phase 1b PRTX-100 dose-escalation study data

Protalex has announced positive preliminary data from Phase 1b dose-escalation study of PRTX-100 in patients with active rheumatoid arthritis (RA).

Ampio to initiate dose escalation run-in study for treatment of knee osteoarthritis

Ampio Pharmaceuticals, Inc. announced today that it's Phase III clinical study of Ampion™ for the treatment for osteoarthritis of the knee will include a dose-escalation run-in study as recommended...

Ampio completes patient enrollment in dose-escalation run-in study of Ampion for treatment of knee osteoarthritis

Ampio Pharmaceuticals, Inc. today announced the completion of patient enrollment in a dose-escalation run-in study to a Phase III pivotal trial evaluating Ampion in the treatment of moderate to severe...

Targeted therapies: Cetuximab dosing by rash—is the scaling of EVEREST meaningful?

The small EVEREST trial has shown that the concept of guiding cetuximab dose escalation using the clinical parameter of acneiform skin rash is safe. However, as no significant increase of cetuximab ef...

Phase 1 dose-escalation study of a siRNA targeting the RTP801 gene in age-related macular degeneration patients

Phase 1 dose-escalation study of a siRNA targeting the RTP801 gene in age-related macular degeneration patients Eye advance online publication, May 25, 2012. doi:10.1038/eye.2012.106 Author...

Lorus Therapeutics Announces Successful Dose Escalation of Its Phase I Clinical Trial of ...

Protalex, Inc. Findings from Phase 1b Dose Escalation Study of PRTX-100 in Patients with Active ...

Astex Pharmaceuticals Announces Results From Dose Escalation Part of SGI-110 Phase 1/2 MDS and AML Study in an Oral Presentation at ASH

DUBLIN, Calif., Dec. 10, 2012 (GLOBE NEWSWIRE) -- Astex Pharmaceuticals, Inc. (Nasdaq:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics,...

Feasibility study of intra-patient sorafenib dose-escalation or re-escalation in patients with previously treated advanced solid tumors.

Purpose To determine if intra-patient dose escalation of the multi-targeted kinase inhibitor sorafenib is feasible in patients with advanced pretreated solid malignancies. Methods An intra-patient dos...

A dose-escalation regimen of trimethoprim-sulfamethoxazole is tolerable for prophylaxis against Pneumocystis jiroveci pneumonia in rheumatic diseases.

OBJECTIVE: To investigate the safety and efficacy of a dose-escalation regimen of trimethoprim-sulfamethoxazole (TMP/SMX) for prophylaxis against Pneumocystis jiroveci pneumonia (PCP) in rheumatic dis...

Dose escalation may be effective in psoriasis patients with treatment failure or suboptimal response, but switching to adalimumab is the most cost-effective measure in different scenarios.

A manuscript recently published in the British Journal of Dermatology discusses the efficacy, safety and cost implications of dose escalation in psoriasis patients with suboptimal response to adalimum...

Effectiveness of adalimumab dose escalation, combination therapy of adalimumab with methotrexate, or both in patients with psoriasis in daily practice.

Abstract Abstract To increase effectiveness of standard adalimumab treatment 40mg every other week (EOW) for patients with psoriasis, dose escalation to 40mg every week or addition of methotrexate (MT...

Escalation with overdose control for phase I drug-combination trials.

Dose finding for combined drugs has grown rapidly in oncology drug development. The escalation with overdose control (EWOC) method is a popular model-based dose-finding approach to single-agent phase...